Faculty Opinions recommendation of Danazol treatment for telomere diseases.

Frederick Naftolin; Ashley L. Comfort

doi:10.3410/f.726363546.793538359

Faculty Opinions recommendation of Danazol treatment for telomere diseases.

Frederick Naftolin, Ashley L. Comfort

In: Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · 2017 · doi:10.3410/f.726363546.793538359 · W4251978803

OA: green CC0

🔓 Open OA copy View on OpenAlex View at publisher

⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

Danazol treatment was investigated for telomere diseases due to the historical efficacy of androgens in marrow failure and the role of sex hormones in telomerase gene expression.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

BACKGROUND-Genetic defects in telomere maintenance and repair cause bone marrow failure, liver cirrhosis, and pulmonary fibrosis, and they increase susceptibility to cancer. Historically, androgens have been useful as treatment for marrow failure syndromes. In tissue culture and animal models, sex hormones regulate expression of the telomerase gene.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

Haematological recovery in dyskeratosis congenita patients treated with danazol 2013

References (42)

Haematological recovery in dyskeratosis congenita patients treated with danazol via openalex
W6675239749 via openalex
W6682741314 via openalex
W6819429540 via openalex
W6831895251 via openalex
doi:10.1182/blood-2008-09-178871 via openalex
doi:10.1038/sj.bmt.1703069 via openalex
doi:10.1016/j.hoc.2009.01.003 via openalex
doi:10.3349/ymj.2005.46.4.471 via openalex
doi:10.1182/blood-2014-10-607572 via openalex
doi:10.1097/01.ju.0000074653.22766.c8 via openalex
doi:10.1038/nrg1656 via openalex
doi:10.1073/pnas.0701009104 via openalex
doi:10.1182/blood-2012-01-403337 via openalex
doi:10.1182/blood.v34.3.283.283 via openalex
doi:10.3324/haematol.2015.129239 via openalex
doi:10.1016/j.mad.2007.11.002 via openalex
doi:10.1016/j.mce.2005.05.009 via openalex
doi:10.1016/j.celrep.2012.08.023 via openalex
doi:10.1016/0002-9343(81)90201-1 via openalex
doi:10.1001/jama.2010.897 via openalex
doi:10.1371/journal.pone.0021485 via openalex
doi:10.3109/10428194.2012.757765 via openalex
doi:10.1038/ng0598-32 via openalex
doi:10.1371/journal.pone.0024383 via openalex
doi:10.1182/blood.v53.3.504.bloodjournal533504 via openalex
doi:10.1371/journal.pone.0113747 via openalex
doi:10.3324/haematol.2011.055269 via openalex
doi:10.1038/nm1578 via openalex
doi:10.1371/journal.pone.0007926 via openalex
doi:10.1111/bjh.12748 via openalex
doi:10.1038/35020592 via openalex
doi:10.1016/0092-8674(85)90170-9 via openalex
doi:10.1007/s00277-012-1454-x via openalex
doi:10.1053/j.gastro.2011.02.058 via openalex
doi:10.1378/chest.10-2545 via openalex
doi:10.1172/jci67146 via openalex
doi:10.1001/jama.2010.1376 via openalex
doi:10.1182/blood-2014-05-526285 via openalex
doi:10.1006/bcmd.2001.0389 via openalex
doi:10.1038/35096585 via openalex
doi:10.1182/blood.v53.3.504.504 via openalex

Source provenance

openalex: last seen: 2026-05-10T11:25:14.011203+00:00

License: CC0 · commercial use OK

[1] Haematological recovery in dyskeratosis congenita patients treated with danazol 2013